Hapvida Participações e Investimentos S.A. (BCBA:HAPV3)
Argentina · Delayed Price · Currency is ARS | Market Cap | 1.63T -46.3% |
| Revenue (ttm) | 8.32T +9.2% |
| Net Income | -37.35B |
| EPS | -74.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 14.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,903 |
| Average Volume | 13,398 |
| Open | 3,900.00 |
| Previous Close | 3,697.50 |
| Day's Range | 3,550.00 - 3,900.00 |
| 52-Week Range | 453.00 - 11,800.00 |
| Beta | n/a |
| RSI | 56.86 |
| Earnings Date | May 11, 2026 |
About BCBA:HAPV3
Hapvida Participações e Investimentos S.A., together with its subsidiaries, operates in the healthcare sector in Brazil. It sells health insurance plans through its own clinical, outpatient, and hospital networks, as well as dental plans through an accredited network. Hapvida Participações e Investimentos S.A. was founded in 1979 and is headquartered in Fortaleza, Brazil. [Read more]
Financial Performance
In 2025, BCBA:HAPV3's revenue was 31.58 billion, an increase of 9.21% compared to the previous year's 28.91 billion. Losses were -141.75 million, -78.17% less than in 2024.
Financial numbers in BRL Financial StatementsNews
Hapvida Participações e Investimentos Earnings Call Transcript: Q4 2025
Q4 2025 results missed expectations due to high MLR and weak member growth, especially in competitive regions. Transformation initiatives, stricter capital discipline, and a CEO transition are underway, with 2026 focused on margin recovery, operational efficiency, and selective growth.
Brazil's Hapvida shares plunge nearly 40% after disappointing Q3 results
Brazilian health provider Hapvida (HAPV3) declared a net profit of R$338 million on Wednesday night, but the third quarter of 2025 proved to be quite disappointing. According to local media outlet Inf...
Hapvida Participações e Investimentos Earnings Call Transcript: Q3 2025
Q3 2025 saw margin pressure from higher utilization and new unit costs, but customer satisfaction and operational metrics improved. Membership growth was below expectations, with robust corporate gains offset by tough competition in other segments. Margin recovery and cost dilution are expected as new units mature and pricing adjustments take effect.
Hapvida Participações e Investimentos Earnings Call Transcript: Q2 2025
Integration completed, with focus shifting to growth, technology, and care quality. Q2 2025 saw 7.3% revenue growth, strong member additions, and improved cost discipline despite one-off provisions. Outlook remains positive with new products, robust pipelines, and continued deleveraging.
Hapvida Participações e Investimentos Earnings Call Transcript: Q1 2025
Net revenue grew 7.3% year-over-year to BRL 7.5 billion, with adjusted EBITDA just over BRL 1 billion and net debt/EBITDA below 1x. Integration and efficiency gains offset litigation pressures, supporting a positive outlook for organic growth and margin expansion in 2025.
Hapvida Participações e Investimentos Earnings Call Transcript: Q4 2024
Concluded a major integration cycle, achieving record financial results in 2024 with revenue up 5.8% and adjusted net income up 170% year-over-year. Entering 2025 with strong cash, improved margins, and a focus on digital transformation and network expansion.
Hapvida Participações e Investimentos Earnings Call Transcript: Q3 2024
Q3 2024 delivered 6.6% revenue growth and strong margin recovery, despite higher provisions for lawsuits due to sector-wide judicialization. Debt leverage fell below 1x EBITDA, and network expansion and digitalization remain top priorities for 2025.
Hapvida Participações e Investimentos Earnings Call Transcript: Q2 2024
Q2 2024 saw strong revenue and margin growth, driven by verticalization, integration, and disciplined pricing. Adjusted EBITDA rose nearly 60% year-over-year, with net debt/EBITDA at 1.03x and robust cash generation supporting network expansion and deleveraging.